179,628 Shares in BioMarin Pharmaceutical Inc. $BMRN Bought by Barrow Hanley Mewhinney & Strauss LLC

Barrow Hanley Mewhinney & Strauss LLC acquired a new stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 179,628 shares of the biotechnology company’s stock, valued at approximately $10,778,000. Barrow Hanley Mewhinney & Strauss LLC owned about 0.09% of BioMarin Pharmaceutical as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Resona Asset Management Co. Ltd. lifted its position in BioMarin Pharmaceutical by 36.9% during the third quarter. Resona Asset Management Co. Ltd. now owns 29,009 shares of the biotechnology company’s stock worth $1,741,000 after purchasing an additional 7,817 shares during the period. Edmond DE Rothschild Holding S.A. grew its position in BioMarin Pharmaceutical by 3.8% in the third quarter. Edmond DE Rothschild Holding S.A. now owns 712,880 shares of the biotechnology company’s stock valued at $42,773,000 after acquiring an additional 25,850 shares during the last quarter. Focus Advisor Solutions LLC raised its stake in BioMarin Pharmaceutical by 61.3% during the third quarter. Focus Advisor Solutions LLC now owns 17,580 shares of the biotechnology company’s stock worth $1,055,000 after acquiring an additional 6,681 shares in the last quarter. Boston Partners raised its stake in BioMarin Pharmaceutical by 44.9% during the third quarter. Boston Partners now owns 222,417 shares of the biotechnology company’s stock worth $13,345,000 after acquiring an additional 68,971 shares in the last quarter. Finally, Global Retirement Partners LLC lifted its holdings in shares of BioMarin Pharmaceutical by 36.9% in the third quarter. Global Retirement Partners LLC now owns 6,718 shares of the biotechnology company’s stock worth $403,000 after acquiring an additional 1,812 shares during the last quarter. Institutional investors own 98.71% of the company’s stock.

Insider Activity at BioMarin Pharmaceutical

In other news, EVP Gregory Friberg sold 5,147 shares of BioMarin Pharmaceutical stock in a transaction on Wednesday, November 18th. The shares were sold at an average price of $58.81, for a total value of $302,695.07. Following the completion of the sale, the executive vice president owned 42,585 shares in the company, valued at $2,504,423.85. The trade was a 10.78% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 0.68% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the stock. Weiss Ratings lowered shares of BioMarin Pharmaceutical from a “sell (d+)” rating to a “sell (d)” rating in a report on Friday, September 18th. BMO Capital Markets reissued an “outperform” rating on shares of BioMarin Pharmaceutical in a research note on Wednesday, September 16th. Jefferies Financial Group increased their price objective on shares of BioMarin Pharmaceutical from $104.00 to $105.00 and gave the company a “buy” rating in a research note on Monday, August 31st. Oppenheimer cut their target price on shares of BioMarin Pharmaceutical from $97.00 to $94.00 and set an “outperform” rating on the stock in a research report on Tuesday, November 3rd. Finally, HC Wainwright reaffirmed a “neutral” rating and set a $60.00 target price on shares of BioMarin Pharmaceutical in a research note on Tuesday, November 3rd. Three equities research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, BioMarin Pharmaceutical presently has an average rating of “Moderate Buy” and a consensus target price of $87.22.

Check Out Our Latest Stock Analysis on BioMarin Pharmaceutical

BioMarin Pharmaceutical Price Performance

Shares of NASDAQ BMRN opened at $60.41 on Friday. The company has a market capitalization of $11.70 billion, a PE ratio of -604.10, a P/E/G ratio of 0.81 and a beta of 0.21. The company has a quick ratio of 1.32, a current ratio of 2.44 and a debt-to-equity ratio of 0.56. BioMarin Pharmaceutical Inc. has a twelve month low of $49.26 and a twelve month high of $70.98. The firm has a fifty day simple moving average of $58.32 and a 200 day simple moving average of $58.55.

BioMarin Pharmaceutical (NASDAQ:BMRN – Get Free Report) last issued its quarterly earnings results on Monday, November 2nd. The biotechnology company reported $0.23 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.28. BioMarin Pharmaceutical had a positive return on equity of 5.58% and a negative net margin of 0.52%. The firm had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1.02 billion. During the same period last year, the business posted $0.12 EPS. The business’s revenue was up 32.0% compared to the same quarter last year. On average, sell-side analysts forecast that BioMarin Pharmaceutical Inc. will post 2.20 EPS for the current year.

BioMarin Pharmaceutical Company Profile

(Free Report)

BioMarin Pharmaceutical is a biotechnology company focused on developing and commercializing medicines for people with rare genetic diseases. Its work includes research, clinical development, manufacturing and distribution of therapies for conditions that often have limited treatment options. The company’s marketed treatments address disorders including phenylketonuria, mucopolysaccharidosis, late-infantile neuronal ceroid lipofuscinosis, achondroplasia and hemophilia A. Its products include Kuvan and Palynziq for phenylketonuria, Vimizim for Morquio A syndrome, Brineura for CLN2 disease, Voxzogo for achondroplasia and Roctavian for hemophilia A. Founded in 1997 and headquartered in San Rafael, California, BioMarin serves patients and healthcare providers in the United States and international markets, including Europe.

See Also

Institutional Ownership by Quarter for BioMarin Pharmaceutical (NASDAQ:BMRN)

Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.